Detalles de la búsqueda
1.
Morphology of immune-mediated hepatitis: A comparison between immune checkpoint inhibitor therapy and combined immune checkpoint inhibitor/anti-angiogenic therapy.
Ann Diagn Pathol;
68: 152225, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38016303
2.
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Ann Surg Oncol;
30(5): 2782-2790, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36178565
3.
Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.
BMC Cancer;
23(1): 416, 2023 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37158833
4.
ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Ann Surg Oncol;
30(5): 2791-2792, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36869918
5.
High platelet counts increase metastatic risk in huge hepatocellular carcinoma undergoing transarterial chemoembolization.
Hepatol Res;
46(10): 1028-36, 2016 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26776560
6.
Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway.
Cell Physiol Biochem;
36(3): 1223-36, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26138883
7.
Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma.
Tumour Biol;
36(11): 8797-803, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26058874
8.
The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization.
Tumour Biol;
36(8): 6045-51, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25731733
9.
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells.
J Pathol;
232(1): 75-86, 2014 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-24122835
10.
Sex-determination gene SRY potentially associates with poor prognosis but not sex bias in hepatocellular carcinoma.
Dig Dis Sci;
60(2): 427-35, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25274159
11.
γ-Glutamyltranspeptidase is a prognostic marker of survival and recurrence in radiofrequency-ablation treatment of hepatocellular carcinoma.
Ann Surg Oncol;
21(9): 3084-9, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24748164
12.
Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma.
J Gastroenterol Hepatol;
29(6): 1273-8, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24955456
13.
Gene-based cancer-testis antigens as prognostic indicators in hepatocellular carcinoma.
Heliyon;
9(3): e13269, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36950598
14.
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Signal Transduct Target Ther;
8(1): 106, 2023 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36928584
15.
Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Ann Surg Oncol;
19(11): 3540-6, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22532305
16.
[Evaluation of the efficacy and prognostic factors for colorectal liver metastases treated with transcatheter arterial chemoembolization].
Zhonghua Zhong Liu Za Zhi;
34(9): 706-9, 2012 Sep.
Artículo
en Zh
| MEDLINE | ID: mdl-23159087
17.
Anti-PD-1 antibodies plus lenvatinib in patients with unresectable hepatocellular carcinoma who progressed on lenvatinib: a retrospective cohort study of real-world patients.
J Gastrointest Oncol;
13(4): 1898-1906, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36092355
18.
Phosphorylation of Thr-516 and Ser-520 in the kinase activation loop of MEKK3 is required for lysophosphatidic acid-mediated optimal IkappaB kinase beta (IKKbeta)/nuclear factor-kappaB (NF-kappaB) activation.
J Biol Chem;
285(11): 7911-8, 2010 Mar 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-20068038
19.
Lysine 63-linked polyubiquitination of TAK1 at lysine 158 is required for tumor necrosis factor alpha- and interleukin-1beta-induced IKK/NF-kappaB and JNK/AP-1 activation.
J Biol Chem;
285(8): 5347-60, 2010 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-20038579
20.
Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma.
Int J Gen Med;
14: 9145-9152, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34880653